Lipid Nanoparticle Vaccine

How an LNP delivers mRNA

The biological problem is brutal: mRNA is one of the most fragile molecules in medicine. Naked mRNA injected into blood is destroyed by RNases in seconds and cannot cross a cell membrane on its own. For decades, this killed every attempt to use mRNA therapeutically — until lipid chemists figured out how to wrap it.

A lipid nanoparticle is an ~80 nm sphere assembled in a microfluidic mixer where lipid-in-ethanol meets mRNA-in-citrate buffer. The acidic pH protonates the ionizable lipid — SM-102 in Moderna's vaccines, ALC-0315 in Pfizer-BioNTech's — turning it cationic, where it grabs the negatively charged mRNA backbone. DSPC (a helper phospholipid) and cholesterol fill in the bilayer; PEG-lipid coats the surface and limits particle growth. The molar ratio in the Spikevax/Comirnaty formulations is roughly 50 : 10 : 38.5 : 1.5 (ionizable : DSPC : cholesterol : PEG).

After intramuscular injection into the deltoid, LNPs are taken up by muscle cells and — more importantly — by resident dendritic immune cells, by clathrin- or caveolae-mediated endocytosis. Inside the endosome, the pH drops to about 5. The ionizable lipid is protonated again, becomes cationic, and disrupts the endosomal membrane. The mRNA spills into the cytosol, finds ribosomes, and translation begins. The encoded spike protein is folded, processed, and presented on MHC class I — and the adaptive immune response begins.

The four lipids, in detail

• Ionizable lipid (~50 mol%). The most important component. SM-102 (Moderna) and ALC-0315 (Pfizer-BioNTech) have a tertiary amine head whose pKa sits around 6.4, low enough to be uncharged at blood pH but cationic in the endosome. Both are ester-linked to enable hepatic clearance — they don't accumulate. The recipe for an ideal ionizable lipid took two decades of structure-activity work (DLin-MC3-DMA, in Onpattro, was the first FDA-approved member).
• Helper phospholipid (~10 mol%). DSPC — distearoylphosphatidylcholine — provides bilayer rigidity. Saturated chains mean the bilayer is gel-like below 55 °C, which stabilizes the particle in storage and circulation.
• Cholesterol (~38.5 mol%). Plugs lipid packing gaps, modulates membrane fluidity, and promotes fusion. Replacing cholesterol with engineered sterols can change biodistribution and transfection efficiency.
• PEG-lipid (~1.5 mol%). A diacyl chain linked to a short polyethylene glycol polymer (typically 2 kDa). It anchors at the surface and projects PEG into solvent, forming a hydration shell that delays opsonization. Because PEG also limits cell uptake, it slowly desorbs from the surface — letting the particle eventually deliver its cargo.

Real numbers — Pfizer vs. Moderna

• mRNA per dose. Comirnaty (Pfizer-BioNTech) uses 30 µg of mRNA per primary adult dose; Spikevax (Moderna) originally used 100 µg, later reduced to 50 µg for boosters.
• LNPs per dose. Roughly 10¹¹ particles, each holding several copies of mRNA.
• Protein yield. Each transfected cell can translate hundreds to thousands of spike proteins from a single mRNA copy before the mRNA is degraded over 1–3 days.
• Efficacy. Both vaccines were >94% effective against symptomatic COVID-19 in their pivotal Phase 3 trials in late 2020.
• Anaphylaxis. Initial estimates were ~5 per million doses, lower than for many vaccines; suspected to be due to anti-PEG IgE in a small fraction of recipients.

A 50-year overhead

The platform looks new. It isn't. Three histories converge into what arrived in our arms in late 2020:

• Liposome science (1965–1990s). Alec Bangham first described lipid vesicles in 1965. Doxil — a liposomal doxorubicin — was approved in 1995, proving lipid-based drug delivery could reach patients.
• Modified mRNA (2005). Katalin Karikó and Drew Weissman showed that replacing uridine with pseudouridine prevented activation of TLR7/8 and made mRNA tolerable for therapeutic use. Their paper was rejected from top journals; Karikó was demoted at Penn. They shared the 2023 Nobel Prize in Medicine.
• Ionizable lipids and microfluidics (1998–2018). Pieter Cullis's group in Vancouver developed DLin-MC3-DMA and microfluidic mixing for siRNA, leading to Onpattro (Alnylam, 2018) — the first FDA-approved LNP drug.

When SARS-CoV-2 was sequenced on 10 January 2020, Moderna had its mRNA-1273 candidate designed within 48 hours. The first human dose was given on 16 March 2020. Emergency Use Authorization arrived on 18 December 2020 — 11 months from sequence to shoulder. That speed only worked because the LNP-mRNA platform was ready years before.

The cold-chain problem

RNA is destroyed by ubiquitous RNase enzymes and even hydrolyzes spontaneously in solution. LNPs can fuse, aggregate, or lose PEG over time. Pfizer-BioNTech's Comirnaty originally required −70 °C dry-ice storage with a brutal 5-day shelf life at 2–8 °C — a logistical nightmare in low-resource settings. Reformulations have relaxed this: −25 to −15 °C for 2 weeks and 2–8 °C for up to 31 days. Moderna's higher cholesterol fraction and different PEG-lipid let it sit at −20 °C long term. Lyophilized (freeze-dried) LNPs and self-amplifying RNA constructs (saRNA, lower doses) are active research directions for tropical distribution.

Common clinical pitfalls and misconceptions

• "mRNA changes your DNA." It cannot. mRNA never enters the nucleus and there is no reverse transcriptase in human cells to convert it back to DNA. The mRNA is degraded within days.
• "The vaccine stays in your body forever." Both mRNA and the LNP lipids are cleared. Spike protein expression is detectable for a few days; the immune memory it generates is what persists.
• "Lipid nanoparticles travel everywhere in the body." Biodistribution is heavily liver- and injection-site-biased — minor amounts in spleen, lymph nodes, ovaries. Trace fluorescence anywhere doesn't equal biological activity at that site.
• PEG anaphylaxis fear. Real but rare (~5 per million). Most cross-reactive PEG anaphylaxis cases were in people with prior severe allergies; observation periods are 15–30 minutes after dosing.
• Confusing the LNP with the antigen. The LNP is only a delivery vehicle. The same particle can carry any mRNA — that's why we have COVID, RSV, flu, CMV, and cancer LNP vaccines all sharing the platform.

LNP-mRNA vs. older vaccine platforms

Property	LNP-mRNA	Adenovirus vector	Protein subunit	Inactivated virus
Time from sequence to candidate	~Days	Weeks	Months	Months
Antigen production site	Patient's own cells	Patient's own cells	Lab bioreactor	Cultured pathogen
Genetic integration risk	None	Extremely rare (transient DNA episome)	None	None
Cold-chain demand	−70 °C → −20 °C → 2–8 °C	2–8 °C	2–8 °C	2–8 °C
Anti-vector immunity issue	Anti-PEG (small)	Strong — limits boosters	None	None
Manufacturing scalability	Very high (cell-free synthesis)	Moderate	Moderate	Slow (need pathogen)
Examples	Comirnaty, Spikevax, mRNA-4157	J&J COVID, AstraZeneca, Ebola	Novavax, hep B, HPV	Flu shot, polio (IPV), hep A